Analyst Activity – Ladenburg Thalmann Financial Services Reiterates Buy on Axsome Therapeutics (NASDAQ:AXSM)

Analyst Ratings For Axsome Therapeutics (NASDAQ:AXSM)

Story continues below

Today, Ladenburg Thalmann Financial Services reiterated its Buy rating on Axsome Therapeutics (NASDAQ:AXSM) with a price target of $31.00.

There are 5 buy ratings on the stock.

The current consensus rating on Axsome Therapeutics (NASDAQ:AXSM) is Buy (Score: 3.00) with a consensus target price of $19.60 per share, a potential 218.70% upside.

Some recent analyst ratings include

  • 7/26/2017-Ladenburg Thalmann Financial Services Reiterated Rating of Buy.
  • 6/20/2017-Aegis Reiterated Rating of Buy.
  • 5/19/2017-BTIG Research initiated coverage with a Buy rating.
  • 10/3/2016-Brean Capital initiated coverage with a Buy rating.

Recent Insider Trading Activity For Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics (NASDAQ:AXSM) has insider ownership of 35.20% and institutional ownership of 32.93%.

  • On 12/23/2015 Randall Kaye, Insider, bought 1,000 with an average share price of $9.03 per share and the total transaction amounting to $9,030.00. View SEC Filing

Recent Trading Activity for Axsome Therapeutics (NASDAQ:AXSM)
Shares of Axsome Therapeutics closed the previous trading session at 6.15 up +0.45 7.89% with 92,055 shares trading hands.

An ad to help with our costs